Cep290
rd16 mouse carries an in-frame deletion of exons [16] [17] [18] [19] and interestingly, predominantly exhibits early onset severe retinal degeneration. No other systemic manifestations were observed. Such a retina-restricted phenotype was attributed to the expression of a partially functional deleted variant of CEP290, in the Cep290 rd16 mouse, which might spare other cell types but was detrimental to photoreceptors. Building upon these observations, CEP290 mutations, particularly a deep intronic homozygous CEP290 mutation, c.2991 + 1665A>G, were reported in isolated cases of childhood blindness disorder, Leber congenital amaurosis (LCA) (12) . This mutation creates a cryptic exon between exons 26 and 27 with a premature stop codon in the CEP290 gene. Curiously, patient lymphocytes carrying this intronic mutation express, albeit at lower level the wild type CEP290 transcript as well (12) . Thus, it was hypothesized that non-retinal cell types may escape the splice defect more efficiently and result in the production of nearnormal normal levels of the full-length CEP290 transcript; however, such a mechanism might not be functional in the photoreceptors. Investigating such mechanisms is key to our understanding of the molecular underpinnings of the manifestation of retina-specific disease due to CEP290 mutations.
In a recent study, Parfitt et al. (13) took on this challenging question. They resorted to induced pluripotent stem cells (iPSCs) to not only investigate the disease mechanisms but also to develop rational therapeutic modalities. They generated iPSCs from fibroblasts (14, 15) of control subjects or from CEP290-LCA patients carrying the deep intronic mutation c.2991 + 1665A>G. Using previously published procedures they differentiated the iPSCs into optic cups and the RPE (16) . The authors then compared the effect of the mutation on the splicing of the CEP290 gene in the iPSCs as well as in the differentiated 3-dimensional (3D) optic cups (to induce retina and photoreceptor formation) and the RPE. The authors first found that the three cell types derived from control fibroblasts exhibited differential regulation of the CEP290 transcription levels. This observation led them to hypothesize that differential expression of the CEP290 gene may underlie a tissue-specific effect of some CEP290 mutations. Commensurately, they found that such regulation is altered due to the deep intronic mutation. It resulted in aberrant splicing of the CEP290 gene and concomitantly reduced CEP290 protein levels in the mutant iPSCs as compared to controls. The mutant iPSCs derived retinas and photoreceptors exhibited relatively severe deregulation of CEP290 expression; they exhibited fewer cilia predominantly in the photoreceptors and defective cilia formation and localization of retinitis pigmentosa GTPase regulator (RPGR), a CEP290-interacting retinal ciliopathy protein (17, 18) and small GTPase RAB8A.
Antisense oligonucleotide (AON)-mediated splice modulation is a powerful tool to correct splice site defects in disease genes. In fact, AON-mediated correction of the c.2991 + 1665A > G CEP290 mutation in patientderived fibroblasts was demonstrated in two independent studies (19, 20) . The corrected gene exhibited improved transcription of the wild type transcript and restoration of cilia formation in the patient fibroblasts. Building upon the success of these studies, Parfitt et al., designed a 25-bp antisense morpholino (MO) against the c.2991 + 1665A>G CEP290 mutation and tested its efficacy. They found that the CEP290-MO reduced the levels of the cryptic exon inclusion and resulted in a concomitant increase in the normal transcript levels in LCA fibroblasts. The CEP290-MO treatment also restored ciliation defects and ciliary protein trafficking of RPGR, and of opsins in the 3D-optic cup derived photoreceptors (13) .
The differentiated retinal tissue has provided an excellent platform to also assess the efficacy of other gene correction strategies, such as genome editing. However, such approaches will have to be continuously designed and modified to fit the patient mutation. Future studies should also focus on utilizing the differentiated tissues from patients to explore the efficacy of mutation-independent approaches. Previous studies using the Cep290 rd16 mouse and the zebrafish have identified potential pathway intermediates that can be exploited to mitigate or delay photoreceptor degeneration due to the loss of CEP290 (21, 22) . Such approaches can also be readily tested in the differentiated optic cups. Taken together, the results of Parfitt et al. provide a valuable clue to our understanding of the tissue-enriched or tissue-specific disease manifestations in several clinically heterogeneous ciliopathies. In addition, this study has opened new and exciting avenues to design and test novel therapeutic modalities for several blinding diseases.
